Androgenetic Alopecia (AGA)
Conditions
Brief summary
Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and emotional impact on those affected. Various therapies are currently approved for the treatment of AGA in men and women, including topical minoxidil, topical or systemic finasteride, platelet-rich plasma and hair transplantation. In addition to these pharmacological and surgical interventions, laser therapies including thulium laser with growth factors have gained popularity. Despite the clinical use of the thulium laser with growth factors in combination with LED phototherapy, there are only a few studies to date that have adequately investigated the objective and patient-side benefits of this therapy.
Interventions
PROCEDUREThulium laser + growth factor serum + LED
3 sessions at intervals of 6 weeks
PROCEDUREThulium laser + growth factor serum
3 sessions at intervals of 6 weeks
PROCEDUREThulium laser
3 sessions at intervals of 6 weeks
Sponsors
Universitätsklinikum Hamburg-Eppendorf
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women aged 18 and over * Good general health, no relevant previous illnesses * Presence of an AGA * Cognitive ability and willingness to give consent (informed consent) * Be willing and able to attend follow-up visits
Exclusion criteria
* Age \< 18 years * Pregnant or breastfeeding women * Scarring alopecia, alopecia due to dermatoses (e.g. lichen ruber, lupus erythemodes,...), alopecia due to chemical or physical noxae, and other non-AGAs * Significant scarring of the region to be treated * Significant open wounds or lesions in the region to be treated * Metallic implants in the head region * Mental illnesses (psychoses, body perception disorders) * Use of isotretinoin or other retinoids, psychotropic drugs, coumarins or heparins in the last 2 weeks * Resurfacing (fractional, ablative, non-ablative) of the affected region \< 2 months before and during the study period * Tendency to excessive scarring * Lack of informed consent and/or data protection declarations
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Subject Global Aesthetic Improvement Scale | 1 and 6 months post-treatment | scale from 0 (very much improved) to 4 (worse) |
| Hair density | at baseline, and 1 and 6 months post-treatment | measurement of hair density before and after treatment |
| hair thickness | at baseline, and 1 and 6 months post-treatment | hair thickness before and after treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| pain intensity | Periprocedural | pain intensity during treatment using a numeric rating scale from 0 (no pain) to 10 (unbearable pain) |
Countries
Germany
Contacts
Primary ContactLynhda Nguyen, Dr. med.
Outcome results
None listed